The role of PET in target localization for radiotherapy treatment planning

Onkologie

Volumn 31, Issue 1-2, 2008, Pages 57-62

  Rembielak, A ^a   Price, P ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Positron emission tomography (PET); Radiotherapy planning; Target volume

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE; METENKEPHALIN; METHIONINE C 11;

BRACHYTHERAPY; BRAIN CANCER; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; GLIOMA; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RECTUM CANCER; REVIEW; TREATMENT PLANNING; UTERINE CERVIX CANCER;

CARCINOMA, NON-SMALL-CELL LUNG; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG NEOPLASMS; LYMPHATIC IRRADIATION; LYMPHOMA; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIATION INJURIES; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 39149145449     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112207     Document Type: Review

References (59)

1. 18F]FHPG. Eur J Nucl Med 2001;28:5-12.
2. Vaupel P, Mayer A: Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-239.
3. Greco C, Rosenzweig K, Cascini GL, Tamburrini O: Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 2007;57:125-134.
4. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, Fidler V, Pruim J, Groen HJ: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-261.
5. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, Lutolf UM, Steinert HC, Von Schulthess GK: Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003;57:853-863.
6. Gregoire V, Haustermans K, Geets X, Roels S, Lonneux M: PET-based treatment planning in radiotherapy: a new standard? J Nucl Med 2007;48(suppl 1):68S-77S.
7. Mac Manus MP, Hicks RJ, Ball DL, Kalff V, Matthews JP, Salminen E, Khaw P, Wirth A, Rischin D, McKenzie A: F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001;92:886-895.
8. Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, Bosch W, Bertrand RJ: Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:78-86.
9. Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rube C, Kirsch CM: Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 2005;46:1342-1348.
10. van Baardwijk A, Bosmans G, Boersma L, Buijsen J, Wanders S, Hochstenbag M, van Suylen RJ, Dekker A, Dehing-Oberije C, Houben R, Bentzen SM, van Kroonenburgh M, Lambin P, De Ruysscher D: PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 2007;68:771-778.
11. Ashamalla H, Rafla S, Parikh K, Mokhtar B, Goswami G, Kambam S, Abdel-Dayem H, Guirguis A, Ross P, Evola A: The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 2005;63:1016-1023.
12. Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, Humm JL, Squire OD, Chui CS, Larson SM, Yorke ED: Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002;62:51-60.
13. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, De Leyn PR, De Wever W, Verbeken EK, Gatti GG, Huyskens DP, Kutcher GJ: The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000;55:317-324.
14. van Baardwijk A, Baumert BG, Bosmans G, van Kroonenburgh M, Stroobants S, Gregoire V, Lambin P, De Ruysscher D: The current status of FDGPET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 2006;32:245-260.
15. Devic S, Tomic N, Faria S, Dean G, Lisbona R, Parker W, Kaufman C, Podgorsak EB: Impact of 18FDG-PET/CT on biological target volume (BTV) definition for treatment planning for non-small cell lung cancer patients. Nucl Instrum Methods Phys Res Sect A: Accelerators, Spectrometers, Detectors Associated Equipment 2007;571:89-92.
16. Giraud P, Grahek D, Montravers F, Carette MF, Deniaud-Alexandre E, Julia F, Rosenwald JC, Cosset JM, Talbot JN, Housset M, Touboul E: CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 2001;49:1249-1257.
17. van Der Wel A, Nijsten S, Hochstenbag M, Lamers R, Boersma L, Wanders R, Lutgens L, Zimny M, Bentzen SM, Wouters B, Lambin P, De Ruysscher D: Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys 2005;61:649-655.
18. Patz EF Jr, Lowe VJ, Goodman PC, Herndon J: Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 1995;108:1617-1621.
19. Rohren EM, Turkington TG, Coleman RE: Clinical applications of PET in oncology. Radiology 2004;231:305-332.
20. Kiffer JD, Berlangieri SU, Scott AM, Quong G, Feigen M, Schumer W, Clarke CP, Knight SR, Daniel FJ: The contribution of 18F-fluoro-2-deoxyglucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 1998;19:167-177.
21. De Ruysscher D, Wanders S, van Haren E, Hochstenbag M, Geeraedts W, Utama I, Simons J, Dohmen J, Rhami A, Buell U, Thimister P, Snoep G, Boersma L, Verschueren T, van Baardwijk A, Minken A, Bentzen SM, Lambin P: Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 2005;62:988-994.
22. Mah K, Caldwell CB, Ung YC, Danjoux CE, Balogh JM, Ganguli SN, Ehrlich LE, Tirona R: The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002;52:339-350.
23. Holloway CL, Robinson D, Murray B, Amanie J, Butts C, Smylie M, Chu K, McEwan AJ, Halperin R, Roa WH: Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer. Radiother Oncol 2004;73:285-287.
24. Caldwell CB, Mah K, Ung YC, Danjoux CE, Balogh JM, Ganguli SN, Ehrlich LE: Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 2001;51:923-931.
25. Fox JL, Rengan R, O'Meara W, Yorke E, Erdi Y, Nehmeh S, Leibel SA, Rosenzweig KE: Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer? Int J Radiat Oncol Biol Phys 2005;62:70-75.
26. Steenbakkers RJ, Duppen JC, Fitton I, Deurloo KE, Zijp LJ, Comans EF, Uitterhoeve AL, Rodrigus PT, Kramer GW, Bussink J, De Jaeger K, Belderbos JS, Nowak PJ, van Herk M, Rasch CR: Reduction of observer variation using matched CTPET for lung cancer delineation: a three-dimensional analysis. Int J Radiat Oncol Biol Phys 2006;64:435-448.
27. Kostakoglu L, Goldsmith SJ: Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000;27:1564-1578.
28. Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ: Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002;94:879-888.
29. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL: Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 2005;237:1038-1045.
30. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN: 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603-609.
31. Lee YK, Cook G, Flower MA, Rowbottom C, Shahidi M, Sharma B, Webb S: Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. Radiother Oncol 2004;73:277-283.
32. Vrieze O, Haustermans K, De Wever W, Lerut T, Van Cutsem E, Ectors N, Hiele M, Flamen P: Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol 2004;73:269-275.
33. Kneist W, Schreckenberger M, Bartenstein P, Grunwald F, Oberholzer K, Junginger T: Positron emission tomography for staging esophageal cancer: does it lead to a different therapeutic approach? World J Surg 2003;27:1105-1112.
34. Leong T, Everitt C, Yuen K, Condron S, Hui A, Ngan SY, Pitman A, Lau EW, MacManus M, Binns D, Ackerly T, Hicks RJ: A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol 2006;78:254-261.
35. Howard A, Mehta MP, Ritter MA, Bradley KA, Tome WA, Chappell RJ, Manon RR, Allen GW: The value of PET/CT in gross tumor volume delineation in lung and esophagus cancer. Int J Radiat Oncol Biol Phys 2004;60:S536.
36. Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H, Gregoire V: Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004;233:93-100.
37. Heron DE, Andrade RS, Flickinger J, Johnson J, Agarwala SS, Wu A, Kalnicki S, Avril N: Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report. Int J Radiat Oncol Biol Phys 2004;60:1419-1424.
38. Schwartz DL, Ford EC, Rajendran J, Yueh B, Coltrera MD, Virgin J, Anzai Y, Haynor D, Lewellen B, Mattes D, Kinahan P, Meyer J, Phillips M, Leblanc M, Krohn K, Eary J, Laramore GE: FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck 2005;27:478-487.
39. Ford EC, Kinahan PE, Hanlon L, Alessio A, Rajendran J, Schwartz DL, Phillips M: Tumor delineation using PET in head and neck cancers: threshold contouring and lesion volumes. Med Phys 2006;33:4280-4288.
40. Scarfone C, Lavely WC, Cmelak AJ, Delbeke D, Martin WH, Billheimer D, Hallahan DE: Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med 2004;45:543-552.
41. Gagel B, Reinartz P, Dimartino E, Zimny M, Pinkawa M, Maneschi P, Stanzel S, Hamacher K, Coenen HH, Westhofen M, Bull U, Eble MJ: pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2′-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004;180:616-622.
42. Gross MW, Weber WA, Feldmann HJ, Bartenstein P, Schwaiger M, Molls M: The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 1998;41:989-995.
43. Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomily RC, Hummel S, Scharnhorst J, Krohn KA, Spence AM: Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 2002;43:1667-1673.
44. Solberg TD, Agazaryan N, Goss BW, Dahlbom M, Lee SP: A feasibility study of 18F-fluorodeoxyglucose positron emission tomography targeting and simultaneous integrated boost for intensity-modulated radiosurgery and radiotherapy. J Neurosurg 2004;101(suppl 3):381-389.
45. Levivier M, Wikier D, Goldman S, David P, Metens T, Massager N, Gerosa M, Devriendt D, Desmedt F, Simon S, Van Houtte P, Brotchi J: Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: early experience with brain tumors. Technical note. J Neurosurg 2000;93(suppl 3):233-238.
46. Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, Klein JC, Herholz K, Heiss W-D: Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163-7170.
47. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L: [11C]Methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol 2006;27:1432-1437.
48. Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K: Value of O-(2-[18F] fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464-1470.
49. Hustinx R, Pourdehnad M, Kaschten B, Alavi A: PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am 2005;43:35-47.
50. Beuthien-Baumann B, Hahn G, Winkler C, Heubner G: Differentiation between recurrent tumor and radiation necrosis in a child with anaplastic ependymoma after chemotherapy and radiation therapy. Strahlenther Onkol 2003;179:819-822.
51. Esthappan J, Mutic S, Malyapa RS, Grigsby PW, Zoberi I, Dehdashti F, Miller TR, Bosch WR, Low DA: Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 2004;58:1289-1297.
52. Malyapa RS, Mutic S, Low DA, Zoberi I, Bosch WR, Laforest R, Miller TR, Grigsby PW: Physiologic FDG-PET three-dimensional brachytherapy treatment planning for cervical cancer. Int J Radiat Oncol Biol Phys 2002;54:1140-1146.
53. Mutic S, Grigsby PW, Low DA, Dempsey JF, Harms WB, Laforest R, Bosch WR, Miller TR: PET-guided three-dimensional treatment planning of intracavitary gynecologic implants. Int J Radiat Oncol Biol Phys 2002;52:1104-1110.
54. Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, Spaulding MB: Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206:755-760.
55. Lammering G, De Haas D, De Ruysscher D, van Kroonenburgh M, Beets-Tan R, Minken A, Lambin P: First report on the use of a dedicated combined CT-PET simulator in rectal cancer patients. Radiother Oncol 2004;ESTRO 23(abstr book):S441.
56. Engelen SM, Beets GL, Beets-Tan RG: Role of preoperative local and distant staging in rectal cancer. Onkologie 2007;30:141-145.
57. von Rohr L, Klaeser B, Joerger M, Kluckert T, Cerny T, Gillessen S: Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie 2007;30:320-323.
58. Junker K, Lindner M, Schütte W, Stahel R: Diagnostik und Therapie des Pleuramesothelioms. Onkologie 2007;30(suppl 1):7-10.
59. Hain SF: Positron emission tomography in urooncology. Cancer Imaging 2005;5:1-7.